Abstract:A series of novel substituted triazines bearing a benzimidazole scaffold were designed and synthesized based on the structures of known anti-cancer agents, namely gedatolisib and alpelisib. All the target compounds were screened for inhibitory activity against PI3Kα and mTOR kinases. Notably, most analogs exhibited IC50 in the nanomolar range. Investigation of the isozyme selectivity indicated that the compounds exhibited remarkable inhibitory activity against PI3Kδ, especially compound 19f showed an IC50 value of 2.3 nM for PI3Kδ and moderate δ-isozyme selectivity over other class I PI3K isoforms and mTOR (with IC50 values of 14.6, 34.0, 849.0 and 15.4 nM for PI3Kα, β, γ and mTOR, respectively). An in vitro MTT assay was conducted to assess the antiproliferative and cytotoxic effects of the prepared analogs. It was revealed that the compounds displayed significant inhibitory activities against the HCT116 human colon cancer cell line. Compound 19i showed 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC50 values). Phosphoblot studies demonstrated that 19c and 19i could significantly suppress the PI3K/Akt/mTOR signaling pathway at 10 μM. Moreover, analogs 19b, 19c and 19i displayed better stability in artificial gastric fluids than gedatolisib, while 19i was indicated not very stable in rat liver microsomes, and may occur phase I metabolic transformations.

Synthesis and Sar of Novel 4-Morpholinopyrrolopyrimidine Derivatives As Potent Phosphatidylinositol 3-Kinase Inhibitors

Development of small-molecule inhibitors that target PI3K13

Development of small-molecule inhibitors that target PI3Kβ

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5 '-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (Pki-587), A Highly Efficacious Dual Inhibitor

Small Molecules Targeting Phosphoinositide 3-Kinases

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.

Novel Imidazolopyrimidines As Dual PI3-Kinase/mTOR Inhibitors

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

Design, Synthesis and Biological Evaluation of Substituted 2-(Thiophen-2-yl)-1,3,5-triazine Derivatives As Potential Dual PI3Kα/mTOR Inhibitors.

Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.

Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-A]pyridine and Quinazolin-4(3H)-one Derivatives As PI3Kα Inhibitors.

Phospshoinositide 3-Kinase (pi3k)/mammalian Target of Rapamycin (mtor) Dual Inhibitors: Discovery and Structure-Activity Relationships of A Series of Quinoline and Quinoxaline Derivatives

Function-oriented synthesis of Imidazo[1,2- a ]pyrazine and Imidazo[1,2- b ]pyridazine derivatives as potent PI3K/mTOR dual inhibitors

Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors